|
|
|
Assessment of ovarian reserve with anti-Mullerian hormone in women following allogeneic hematopoietic cell transplantation |
A.H. Kaya1, *( ), E. Tekgunduz1, S. Akpınar1, G. Bozdağ2, T.N. Yiğenoğlu1, A. Merdin1, S. Namdaroglu1, O. Kayıkcı1, F. Altuntaş1 |
1 Hematology Clinic and Bone Marrow Transplantation Unit, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey 2 Department of Obstetrics and Gynecology, Hacettepe University School of Medicine, Ankara, Turkey |
|
|
Abstract Introduction: Severe ovarian failure and persistent infertility have could be seen in females following allogeneic hematopoietic cell transplantation (allo-HCT.) In this study, the authors aimed to determine the effectiveness of AMH on assessment of ovarian reserve in long-term survivors after allo-HCT. Material and Methods: Female patients, who underwent allo-HCT between August 2009 and February 2016, were retrospectively evaluated for ovarian capacity in long-term follow-up. Twenty-one female patients with a median age of 34 (22-45) years were included in the study. The serum levels of estrogen (E2), follicle stimulated hormone (FSH), luteinizing hormone (LH), and AMH were analysed. Results: The median duration of post-transplant follow-up was 37 (12-84) months. Primary ovarian failure (POF) was detected in eight (38,1%) and 19 (90,4%) cases in the pre-transplant and post-transplant period, respectively. It was found that no menstruation cycles were observed in 18 cases with low AMH levels. Discussion: Regular menstrual cycles may not guarantee the fertilization in the post-transplant period. Combined analysis of hormonal investigations, antral follicle count by vaginal USG, and evaluation of serum AMH levels may be preferred to demonstrate the presence of POF.
|
Published: 10 February 2019
|
*Corresponding Author(s):
A.H. KAYA
E-mail: dr.alihakan@gmail.com
|
Cite this article:
A.H. Kaya, E. Tekgunduz, S. Akpınar, G. Bozdağ, T.N. Yiğenoğlu, A. Merdin, S. Namdaroglu, O. Kayıkcı, F. Altuntaş. Assessment of ovarian reserve with anti-Mullerian hormone in women following allogeneic hematopoietic cell transplantation. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 127-130.
URL:
https://ceog.imrpress.com/EN/10.12891/ceog4552.2019 OR https://ceog.imrpress.com/EN/Y2019/V46/I1/127
|
No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|